29 Sep 2021 News Analyzing the synthesis route of tert-Butyl 3-methylpiperazine-1-carboxylate

120737-59-9, The synthetic route of 120737-59-9 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.120737-59-9,tert-Butyl 3-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

[Referential Example 21] 3,4-Dimethylpiperazine-1-carboxylic acid tert-butyl ester 10percent Palladium-carbon (0.59 g), 35percent aqueous formalin (9.7 mL), and 1M HCl-ethanol (31.3 mL) were added to a solution of 3-methylpiperazine-1-carboxylic acid tert-butyl ester (5.70 g) obtained in Referential Example 20 in methanol (100 mL) at room temperature, and the mixture was stirred for 15 hours in a hydrogen atmosphere. The reaction mixture was purged with nitrogen, and insoluble matter was removed through filtration. The solvent of the filtrate was removed under reduced pressure, and chloroform-methanol (9percent) was added to the residue. The mixture was alkalified with aqueous sodium hydroxide and then partitioned. The aqueous layer was extracted with chloroform – methanol (9percent), and the organic layers were combined, washed with saturated brine, and dried over sodium sulfate anhydrate. After a filtration step, the solvent was removed under reduced pressure, and the residue was purified through silica gel column chromatography (chloroform – methanol), to thereby give the title compound as an oil (3.10 g, 51percent). 1H-NMR (400MHz, CDCl3) delta: 1.04 (3H, d, J=6. 3Hz), 1.46(9H,s), 1.95-2.20(2H,m), 2.28(3H,s), 2.50-2.78(2H,br), 2. 90-3.05 (1H,br), 3.88 (1H, br). MS (ESI)m/z:215 (M+H)+.

120737-59-9, The synthetic route of 120737-59-9 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; DAIICHI PHARMACEUTICAL CO., LTD.; EP1621537; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics